Outperforming Pharma Stock Still Has Upside Potential

Teva Pharmaceuticals Industries (NYSE:TEVA) is moving 2.9% lower to trade at $36.41, pulling back from its Aug. 27, nearly nine-year high of $38.36.

Schaeffers Research • 10 hours ago

TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study

Teva's TEV '408 meets its phase IIa celiac disease goal, preventing gluten-induced intestinal damage and showing a favorable safety profile.

Zacks Investment Research • 12 hours ago

Teva's immune disorder drug meets main goal in mid-stage trial

Israeli drugmaker Teva Pharmaceutical Industries , said on Wednesday its experimental drug helped prevent gluten-related intestinal damage in adults ​with celiac disease, meeting the main goal of a ‌mid-stage trial.

Reuters • Sep 2, 2026

Teva's TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study

Teva Pharmaceutical Industries NYSE: TEVA reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company saying the treatment met its primary endpoint and showed statistically significant effects on key measures of intestinal damage.

MarketBeat • Sep 2, 2026

Teva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) shares are trading higher after the company announced positive topline results from an ongoing Phase 2a study of TEV ‘408.

Benzinga • Sep 2, 2026

Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) on Wednesday reported encouraging topline outcomes from an active Phase 2a clinical trial evaluating TEV ‘408, an experimental anti-interleukin-15 monoclonal antibody, for celiac disease.

Benzinga • Sep 2, 2026

Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study Transcript

Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study Transcript

Seeking Alpha • Sep 2, 2026

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Teva reports positive Phase 2a results for Teva-discovered TEV '408, showing significant prevention of gluten-induced intestinal damage in celiac disease.

GlobeNewsWire • Sep 2, 2026

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

Zacks Investment Research • Sep 1, 2026

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. When finalized, this agreement will support continued investment in scientific innovation and pharmaceutical manufacturing capabilities.    “Teva appreciates the opportunity to work with President Trump and his Administration to expand access and affordability for patients today while enabling continued investment in medicines patients need tomorrow,” said Chris Fox, President, Teva USA. “Teva built its business around delivering affordable medicines to Americans, and we share the Administration's commitment to improve access to more affordable medicines while investing in scientific innovation and domestic manufacturing capabilities in the U.S.”                                                                                                  Teva remains in active discussions with the Trump Administration to strike a deal anchored in all four of the President's drug pricing priorities. If an agreement is reached, Teva would align U.S. Medicaid pricing for select medicines with pricing in leading developed markets through the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) framework. The agreement also would include a prospective Most-Favored-Nation (MFN) commitment for applicable future innovative product launches.  Additionally, Teva has offered a dedicated reserve of certain active pharmaceutical ingredients (API) in support of public health needs and continued investment into U.S. pharmaceutical manufacturing capabilities. Conditions of the negotiation to reach a final agreement remain confidential.

GlobeNewsWire • Aug 31, 2026